Abstract 143P
Background
The combination of local thermal ablation with immune checkpoint inhibitors perioperatively for small hepatocellular carcinoma (HCC) is yet to be explored. The aim of this phase II trial was to evaluate the safety and tolerability of thermal ablation in combination with tislelizumab, an anti-PD-1 antibody, in patients with HCC of Barcelona Clinic Liver Cancer (BCLC) stage A or B, and to make a preliminary evaluation of the efficacy of this treatment modality.
Methods
This phase II trial (NCT04652440) enrolled newly diagnosed and recurrent HCC patients with 1 or 2 lesions of 2-5 cm in size. This study included two stages. The first stage included 6 patients for dose-limited toxicity (DLT) observation. Only if DLT appeared in < 2 patients, the other 24 patients would be included. Enrolled patients received the first dose of tislelizumab intravenously within 1 day before percutaneous thermal ablation, followed by infusions every 3 weeks for totally 4 doses. The primary endpoints were safety and tolerability. Secondary endpoints included the rate of complete response by first ablation (CR1), local recurrence rate, distant metastasis rate, and 1- and 2-year disease-free survival (DFS) and overall survival (OS) rates.
Results
No DLT occurred in the first 6 patients, and the study completed recruiting a total 30 subjects in July 2023. Twenty-six subjects had already finished their study treatment and were followed regularly. One patient withdrew her informed consent after completion of the ablation and the first dose of study medication. The other 3 were still on tislelizumab therapy. Until the time of data cut-off (July 30, 2023), the most common adverse events were increased alanine aminotransferase (N=15) and aspartate aminotransferase (N=19) on the first day after ablation. The majority recovered after supportive treatment. 10 patients experienced grade 1-2 immune-related adverse events (irAEs), the most common were rash (N=8), pruritus (N=5), and anorexia (N=4). No ≥3 grade irAEs occurred.
Conclusions
Thermal ablation combined with tislelizumab showed acceptable safety and tolerability with no unexpected SAEs observed. Results of efficacy will be disclosed in future.
Clinical trial identification
NCT04652440.
Editorial acknowledgement
Legal entity responsible for the study
Sun Yat-sen University Cancer Center.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
154P - Adverse events (AEs) as potential predictive factors of activity in patients with advanced hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (AB)
Presenter: Mara Persano
Session: Poster Display
Resources:
Abstract
155P - Penpulimab combined with anlotinib and nab-paclitaxel plus gemcitabine (PAAG) as first-line treatment for advanced metastatic pancreatic cancer: A prospective, multicenter, single-arm, phase II study
Presenter: Juan Du
Session: Poster Display
Resources:
Abstract
156P - Phase II trial of second-line regorafenib in patients with unresectable hepatocellular carcinoma after progression on first-line atezolizumab plus bevacizumab: REGONEXT trial
Presenter: Jaekyung Cheon
Session: Poster Display
Resources:
Abstract
157P - T/N ratio and radiation dose delivered do not correlate with the development of Radioembolization-Induced Liver Disease (REILD) in Hepatocellular Carcinoma (HCC) following Y90 selective internal radiation therapy (Y90-SIRT): A retrospective, single tertiary centre cohort study
Presenter: Daniel Yang Yao Peh
Session: Poster Display
Resources:
Abstract
158P - Single-cell RNA sequencing via Endoscopic Ultrasoundguided Fine-Needle Biopsy (EUS-FNB) Pancreatic Biopsies uncovered an aggressive subclone with a poor prognosis
Presenter: Yung-yeh Su
Session: Poster Display
Resources:
Abstract
159P - Classical computer vision and modern deep-learning of pancreatic stroma histology features to diagnose cancer
Presenter: Abdelhakim Khellaf
Session: Poster Display
Resources:
Abstract
160P - Interim analysis of the NAPOLEON-2 study: Safety evaluation of nano-liposomal irinotecan with fluorouracil and folinic acid for advanced pancreatic cancer
Presenter: Wataru Kusano
Session: Poster Display
Resources:
Abstract
161P - Screening and COnsensus based on Practices and Evidence (SCOPE): Real-world survey on Japanese and rest-of-world practice patterns in resectable pancreatic cancer
Presenter: Elizabeth Smyth
Session: Poster Display
Resources:
Abstract
162P - Recurrence pattern of hepatocellular carcinoma patients receiving curative surgery of RFA: An update
Presenter: Long Chan
Session: Poster Display
Resources:
Abstract
163P - Chemotherapy versus palliative radiotherapy in advanced inoperable gall bladder cancer
Presenter: Vimal Sekar
Session: Poster Display
Resources:
Abstract